[go: up one dir, main page]

MA53399A - Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine - Google Patents

Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine

Info

Publication number
MA53399A
MA53399A MA053399A MA53399A MA53399A MA 53399 A MA53399 A MA 53399A MA 053399 A MA053399 A MA 053399A MA 53399 A MA53399 A MA 53399A MA 53399 A MA53399 A MA 53399A
Authority
MA
Morocco
Prior art keywords
kallicrein
inhibitors
pyrazoles substituted
human plasmatic
plasmatic
Prior art date
Application number
MA053399A
Other languages
English (en)
Other versions
MA53399B1 (fr
Inventor
Yarlagadda S Babu
Venkat R Chintareddy
Pravin L Kotian
Satish V Kumar
Minwan Wu
Weihe Zhang
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MA53399A publication Critical patent/MA53399A/fr
Publication of MA53399B1 publication Critical patent/MA53399B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA53399A 2014-03-07 2015-03-09 Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine MA53399B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US201461981515P 2014-04-18 2014-04-18

Publications (2)

Publication Number Publication Date
MA53399A true MA53399A (fr) 2021-06-02
MA53399B1 MA53399B1 (fr) 2022-10-31

Family

ID=54055948

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53399A MA53399B1 (fr) 2014-03-07 2015-03-09 Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine

Country Status (32)

Country Link
US (12) US10125102B2 (fr)
EP (3) EP3828173B1 (fr)
JP (4) JP6574435B2 (fr)
KR (2) KR102736869B1 (fr)
CN (2) CN106257976B (fr)
AU (3) AU2015226855C1 (fr)
BR (1) BR112016020199A8 (fr)
CA (2) CA3164693A1 (fr)
CY (2) CY1123810T1 (fr)
DK (2) DK3113772T3 (fr)
EA (1) EA036251B1 (fr)
ES (2) ES2836373T3 (fr)
FR (1) FR21C1048I2 (fr)
HR (2) HRP20221373T1 (fr)
HU (3) HUE052668T2 (fr)
IL (2) IL280785B2 (fr)
LT (3) LT3113772T (fr)
LU (1) LUC00233I2 (fr)
MA (1) MA53399B1 (fr)
MX (2) MX2016011468A (fr)
MY (1) MY199131A (fr)
NL (1) NL301142I2 (fr)
NO (1) NO2022046I1 (fr)
NZ (2) NZ724250A (fr)
PH (1) PH12016501750B1 (fr)
PL (2) PL3113772T3 (fr)
PT (2) PT3113772T (fr)
RS (2) RS61159B1 (fr)
SG (2) SG11201607267SA (fr)
SI (1) SI3113772T1 (fr)
SM (2) SMT202300002T1 (fr)
WO (1) WO2015134998A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228996B (zh) 2013-03-25 2017-11-28 百时美施贵宝公司 作为因子XIa抑制剂的含取代唑类的四氢异喹啉
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
NO2760821T3 (fr) 2014-01-31 2018-03-10
CN110845498B (zh) 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
MX2016011468A (es) 2014-03-07 2017-01-23 Biocryst Pharm Inc Inhibidores de calicreína plasmática humana.
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
US10562850B2 (en) * 2015-10-01 2020-02-18 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
BR112018074395A2 (pt) 2016-05-31 2019-03-06 Kalvista Pharmaceuticals Limited derivados de pirazol como inibidores de calicreína plasmática
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
SMT202200112T1 (it) 2017-11-29 2022-05-12 Kalvista Pharmaceuticals Ltd Forme di dosaggio comprendenti un inibitore della callicreina plasmatica
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2020041301A1 (fr) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
AR116951A1 (es) * 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020210368A1 (fr) * 2019-04-08 2020-10-15 Biocryst Pharmaceuticals, Inc. Inhibiteurs de la kallicréine plasmatique et leurs procédés d'utilisation dans des troubles oculaires
WO2021025969A1 (fr) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Formes à l'état solide de bérotralstat
PE20221009A1 (es) * 2019-08-06 2022-06-15 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
CN114258392A (zh) * 2019-08-21 2022-03-29 卡尔维斯塔制药有限公司 酶抑制剂
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021168320A1 (fr) 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Composés hétéroaryle pour le traitement de troubles médiés par le facteur d du complément
JP7245397B2 (ja) * 2020-03-04 2023-03-23 メッドシャイン ディスカバリー インコーポレイテッド 複素環化合物
CA3182626A1 (fr) * 2020-06-16 2021-12-23 Salman Jabri Inhibiteurs de la kallicreine plasmatique
WO2022060842A1 (fr) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systèmes et méthodes de prédiction de dysfonctionnement de greffe avec des protéines d'exosomes
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (fr) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Support pour medicaments a liberation progressive
JPH05502179A (ja) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド 管状器官内薬剤溶出装具
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
JP2001509145A (ja) * 1996-12-23 2001-07-10 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての窒素を含む複素環式芳香族化合物
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
ATE296805T1 (de) * 1997-06-19 2005-06-15 Bristol Myers Squibb Pharma Co Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
AU1724499A (en) * 1997-12-22 1999-07-12 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
WO2000047558A1 (fr) * 1999-02-10 2000-08-17 Welfide Corporation Composes amide et leur utilisation medicinale
ES2197092T3 (es) * 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2002000651A2 (fr) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
IL155043A0 (en) 2000-09-22 2003-10-31 Bristol Myers Squibb Pharma Co Efficient process for preparation of a factor xa inhibitor
IL157873A0 (en) 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
MY142967A (en) 2001-08-13 2011-01-31 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
EP1417200B1 (fr) * 2001-08-13 2010-06-02 E.I. Du Pont De Nemours And Company Nouveaux 1h-dihydropyrazoles substitues et leurs procedes de preparation et d'utilisation
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
EP1427705A2 (fr) * 2001-09-21 2004-06-16 E.I. Du Pont De Nemours And Company Diamides insecticides
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003099793A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Derives 1,2-azole presentant une activite hypoglycemique et hypolipidemique
BR0311707A (pt) * 2002-06-13 2005-03-15 Du Pont Composto, composição e método de controle de pelo menos uma praga invertebrada
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
AU2004218260A1 (en) 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005094805A1 (fr) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. Dérivé imine et dérivé amide
US20070184018A1 (en) 2004-04-13 2007-08-09 Lahm George P Anthranilamide insecticides
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EA012929B1 (ru) 2004-11-18 2010-02-26 Е.И. Дюпон Де Немур Энд Компани Антраниламидные инсектициды
RU2394021C2 (ru) * 2004-12-07 2010-07-10 Тояма Кемикал Ко., Лтд. Новое производное антраниловой кислоты или его соль
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
US7867949B2 (en) 2005-10-14 2011-01-11 Sumitomo Chemical Company, Limited Hydrazide compound and pesticidal use of the same
JP5186751B2 (ja) * 2005-10-14 2013-04-24 住友化学株式会社 ヒドラジド化合物およびその有害生物防除用途
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
ATE525072T1 (de) 2006-02-09 2011-10-15 Athersys Inc Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen
PL2051975T3 (pl) * 2006-05-16 2013-01-31 Boehringer Ingelheim Int Podstawione prolinamidy, ich wytwarzanie oraz ich zastosowanie jako środków leczniczych
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
EP2079729A1 (fr) 2006-11-03 2009-07-22 Irm Llc Composés et compositions en tant qu'inhibiteurs des protéines kinases
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
WO2008104077A1 (fr) 2007-02-28 2008-09-04 Methylgene Inc. Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt)
WO2008134969A1 (fr) 2007-04-30 2008-11-13 Sinochem Corporation Composés benzamides et leurs applications
CN101298451B (zh) 2007-04-30 2013-01-30 中国中化股份有限公司 苯甲酰胺类化合物及其应用
AU2009328584B2 (en) * 2008-12-18 2016-05-12 Bayer Cropscience Aktiengesellschaft Tetrazole substituted anthranilic acid amides as pesticides
CN102365278B (zh) 2009-03-26 2015-05-06 先正达参股股份有限公司 杀虫化合物
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
WO2011075684A1 (fr) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
AU2011209586B2 (en) 2010-02-01 2016-01-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy
WO2011118818A1 (fr) 2010-03-26 2011-09-29 味の素株式会社 Dérivé d'amidinoaneline
CN102285963B (zh) 2010-06-21 2014-04-09 中国中化股份有限公司 3-甲氧基吡唑酰胺类化合物及其应用
AR082498A1 (es) 2010-08-20 2012-12-12 Gruenenthal Gmbh Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide
WO2012062462A1 (fr) 2010-11-10 2012-05-18 Grünenthal GmbH Carboxamide hétéroaromatique substitué et dérivés de l'urée en tant que ligands du récepteur vanilloïde
EP2702055A1 (fr) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Dérivés pyrazolyl-pyrimidine en tant qu'inhibiteurs des kinases
WO2012142308A1 (fr) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
WO2013036232A2 (fr) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives
KR20140091041A (ko) 2011-11-09 2014-07-18 그뤼넨탈 게엠베하 바닐로이드 수용체 리간드로서의 so2-함유 그룹으로 치환된 페닐 모이어티를 갖는 치환된 피라졸릴계 카복사미드 및 우레아 유도체들
CN103467380B (zh) 2013-09-29 2015-06-24 南开大学 一类取代苯基吡唑酰胺衍生物及其制备方法和应用
MX2016011468A (es) 2014-03-07 2017-01-23 Biocryst Pharm Inc Inhibidores de calicreína plasmática humana.
AR116951A1 (es) 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
PE20221009A1 (es) 2019-08-06 2022-06-15 Biocryst Pharm Inc Sintesis de un inhibidor de calicreina plasmatica a escala de proceso

Also Published As

Publication number Publication date
PH12016501750A1 (en) 2016-11-21
SMT202100031T1 (it) 2021-03-15
LT3828173T (lt) 2022-11-10
KR102510427B1 (ko) 2023-03-14
AU2015226855C1 (en) 2021-02-11
US20180354906A1 (en) 2018-12-13
US20190322626A1 (en) 2019-10-24
BR112016020199A8 (pt) 2021-07-20
US10329260B2 (en) 2019-06-25
CN113307772A (zh) 2021-08-27
CN106257976A (zh) 2016-12-28
LTPA2021524I1 (fr) 2021-11-10
FR21C1048I2 (fr) 2022-09-30
RS63763B1 (sr) 2022-12-30
HUE060660T2 (hu) 2023-04-28
US20170073314A1 (en) 2017-03-16
CN106257976B (zh) 2021-02-02
AU2020260400B2 (en) 2022-08-11
MX2020013059A (es) 2022-10-07
HUE052668T2 (hu) 2021-05-28
SI3113772T1 (sl) 2021-01-29
HRP20201916T1 (hr) 2021-01-22
IL280785A (en) 2021-04-29
CY2021029I2 (el) 2022-03-24
DK3113772T3 (da) 2020-12-07
ES2836373T3 (es) 2021-06-24
NO2022046I1 (no) 2022-11-07
JP2017507160A (ja) 2017-03-16
US11192861B2 (en) 2021-12-07
CA2941380C (fr) 2022-09-06
US20240150295A1 (en) 2024-05-09
KR20230042384A (ko) 2023-03-28
FR21C1048I1 (fr) 2021-12-10
CA2941380A1 (fr) 2015-09-11
EA201691803A1 (ru) 2017-02-28
KR102736869B1 (ko) 2024-12-02
IL280785B2 (en) 2024-09-01
ES2932406T3 (es) 2023-01-18
US10633345B2 (en) 2020-04-28
IL247518B (en) 2021-02-28
HUS2100045I1 (hu) 2021-11-29
US20240150296A1 (en) 2024-05-09
EP3113772A4 (fr) 2017-08-30
US20210047276A1 (en) 2021-02-18
US20230056538A1 (en) 2023-02-23
LUC00233I2 (fr) 2025-02-03
EA036251B1 (ru) 2020-10-20
US20230094305A1 (en) 2023-03-30
US11708333B2 (en) 2023-07-25
EP3828173A1 (fr) 2021-06-02
JP6915003B2 (ja) 2021-08-04
AU2015226855A1 (en) 2016-10-13
PT3113772T (pt) 2020-12-15
JP2023181543A (ja) 2023-12-21
CY2021029I1 (fr) 2022-03-24
HRP20221373T1 (hr) 2023-01-06
IL247518A0 (en) 2016-11-30
AU2022259742A1 (en) 2022-12-01
AU2020260400A1 (en) 2020-11-26
IL280785B1 (en) 2024-05-01
EP3828173B1 (fr) 2022-08-31
PT3828173T (pt) 2022-12-05
CA3164693A1 (fr) 2015-09-11
SMT202300002T1 (it) 2023-03-17
CN113307772B (zh) 2024-06-28
JP2019206588A (ja) 2019-12-05
US11230530B2 (en) 2022-01-25
JP6574435B2 (ja) 2019-09-11
BR112016020199A2 (pt) 2017-08-15
KR20160130254A (ko) 2016-11-10
WO2015134998A1 (fr) 2015-09-11
DK3828173T3 (da) 2022-11-07
US11708332B2 (en) 2023-07-25
LT3113772T (lt) 2020-12-28
RS61159B1 (sr) 2021-01-29
MY199131A (en) 2023-10-17
SG11201607267SA (en) 2016-09-29
PL3828173T3 (pl) 2022-12-19
AU2015226855B2 (en) 2020-09-03
US11685721B2 (en) 2023-06-27
PH12016501750B1 (en) 2023-08-16
EP4180424A1 (fr) 2023-05-17
US20230100082A1 (en) 2023-03-30
US11203574B2 (en) 2021-12-21
US20210078952A1 (en) 2021-03-18
US10125102B2 (en) 2018-11-13
PL3113772T3 (pl) 2021-04-06
CY1123810T1 (el) 2022-03-24
US20210047275A1 (en) 2021-02-18
MA53399B1 (fr) 2022-10-31
EP3113772B8 (fr) 2020-11-25
US10689346B2 (en) 2020-06-23
MX2016011468A (es) 2017-01-23
US12162838B2 (en) 2024-12-10
AU2022259742B2 (en) 2024-09-05
JP2021169499A (ja) 2021-10-28
EP3113772B1 (fr) 2020-09-09
NL301142I2 (nl) 2021-12-09
LTC3113772I2 (fr) 2023-06-26
US12116346B2 (en) 2024-10-15
SG10202001795XA (en) 2020-04-29
US20180258049A1 (en) 2018-09-13
EP3113772A1 (fr) 2017-01-11
NL301142I1 (fr) 2021-11-03
NZ724250A (en) 2022-02-25
NZ762034A (en) 2022-02-25

Similar Documents

Publication Publication Date Title
FR21C1048I2 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
DK3590543T3 (da) Medicinsk forbinding
MA53944A (fr) Inhibiteurs de la glycosidase
DK3107563T3 (da) Glycomålrettede terapeutiske midler
MA39483A (fr) Agents thérapeutiques cibles
DK3151875T3 (da) Humane lever-scaffolds
EP3209331C0 (fr) Solution ophtalmique
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
EP3360010A4 (fr) Source accordable de bi-photons
DK3180315T3 (da) Pyrazoler
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
DK3100747T3 (da) Steriliseret arbejdssystem
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
EP3246047C0 (fr) Médicament d'association
MA43052A (fr) Inhibiteurs de la kallicréine plasmatique humaine
DK3166473T3 (da) Oftalmoskoper
MA41266A (fr) Cataplasme
DK2992967T3 (da) Medikamentdispenser
LT3216451T (lt) Oftalmologinė vandeninė kompozicija
EP3305294A4 (fr) Médicament aqueux
BR112016027580A2 (pt) Formulação de ceritinib
RS63859B1 (sr) N,n-bis-2-merkaptoetil izoftalamid za lečenje neurodegenerativnih bolesti